Salvianic borneol ester reduces β-amyloid oligomers and prevents cytotoxicity

Pharmaceutical Biology

Volumn 49, Issue 10, 2011, Pages 1008-1013

  Han, Mei ^a   Liu, Ying ^a   Zhang, Bing ^a   Qiao, Jinping ^a   Lu, Weidong ^b   Zhu, Yanyan ^a   Wang, Yongyan ^a   Zhao, Changqi ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

amyloid peptide; Alzheimer's disease; Neuroprotection; Salvianic borneol ester; Thioflavin T; Transmission electron microscopy

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; BORNEOL; HERBACEOUS AGENT; HYDROGEN PEROXIDE; NEUROPROTECTIVE AGENT; SALVIANIC ACID A; SALVIANIC BORNEOL ESTER; THIOFLAVINE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN CELL; HYBRIDOMA; MONOTHERAPY; MOTONEURON; NEUROBLASTOMA CELL; NEUROPROTECTION; TRANSMISSION ELECTRON MICROSCOPY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; BORNANES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LACTATES; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OLIGONUCLEOTIDES; PEPTIDE FRAGMENTS; PHYTOTHERAPY; SALVIA;

LAMIACEAE; SALVIA MILTIORRHIZA;

EID: 80053064706     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2011.559585     Document Type: Article

References (28)

1. Behl C. (1997). Amyloid beta-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res, 290, 471-480. (Pubitemid 27522250)
2. 2-induced oxidative stress in astrocytes primary cultures. Neurosci Lett, 442, 224-227.
3. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. (2005). Natural oligomers of the amyloid-beta protein specifcally disrupt cognitive function. Nat Neurosci, 8, 79-84. (Pubitemid 41236735)
4. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Kraft GA, LaDu MJ. (2002). Oligomeric and fbrillar species of amyloid-beta peptides diferentially afect neuronal viability. J Biol Chem, 277, 32046-32053. (Pubitemid 34969015)
5. Fujiwara H, Iwasaki K, Furukawa K, Seki T, He M, Maruyama M, Tomita N, Kudo Y, Higuchi M, Saido TC, Maeda S, Takashima A, Hara M, Ohizumi Y, Arai H. (2006). Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation efects on Alzheimer's beta-amyloid proteins. J Neurosci Res, 84, 427-433. (Pubitemid 44126295)
6. Han M, Zhao CQ, Wang YY. (2009). β-(3, 4-Dihydroxyphenyl)-α- hydroxypropanoates as amyloid peptide inhibitors and their preparation, pharmaceutical compositions and use in the treatment of neurodegenerative diseases. Faming Zhuanli Shenqing Gongkai Shuomingshu, Chinese patent, 21 pp. CN 101475483, A 20090708, CAN 151:220848, AN 2009: 840155.
7. Hardy JA, Higgins GA. (1992). Alzheimer's disease: Te amyloid cascade hypothesis. Science, 256, 184-185.
8. Hawkes CA, Ng V, McLaurin J. (2009). Small molecule inhibitors of Aβ-aggregation and neurotoxicity. Drug Dev Res, 70, 111-124.
9. Hirohata M, Ono K, Yamada M. (2008). Non-steroidal anti-infammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des, 14, 3280-3294.
10. Jakob-Roetne R, Jacobsen H. (2009). Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl, 48, 3030-3059.
11. Jan A, Hartley DM, Lashuel HA. (2010). Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research. Nat Protoc, 5, 1186-1209.
12. Klunk WE, Jacob RF, Mason RP. (1999). Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem, 266, 66-76. (Pubitemid 29024609)
13. Lin HQ, Ho MT, Lau LS, Wong KK, Shaw PC, Wan DC. (2008). Anti-acetylcholinesterase activities of traditional Chinese medicine for treating Alzheimer's disease. Chem Biol Interact, 175, 352-354.
14. Lleó A, Greenberg SM, Growdon JH. (2006). Current pharmacotherapy for Alzheimer's disease. Annu Rev Med, 57, 513-533. (Pubitemid 43262005)
15. Mecocci P, Mariani E, Polidori MC, Hensley K, Butterfeld DA. (2008). Antioxidant agents in Alzheimer's disease. Cent Nerv Syst Agents Med Chem, 8, 48-63. (Pubitemid 351468882)
16. Mei Z, Zhang F, Tao L, Zheng W, Cao Y, Wang Z, Tang S, Le K, Chen S, Pi R, Liu P. (2009). Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro. Neurosci Lett, 452, 90-95.
17. Porat Y, Abramowitz A, Gazit E. (2006). Inhibition of amyloid fbril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des, 67, 27-37. (Pubitemid 43881385)
18. Reinke AA, Gestwicki JE. (2007). Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: infuence of linker length and fexibility. Chem Biol Drug Des, 70, 206-215. (Pubitemid 47305405)
19. Ren Y, Houghton PJ, Hider RC, Howes MJ. (2004). Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med, 70, 201-204. (Pubitemid 38445184)
20. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. (2008). Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother, 62, 199-207. (Pubitemid 351635842)
21. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. (2002). Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med, 32, 1076-1083. (Pubitemid 34603345)
22. Yankner BA, Dufy LK, Kirschner DA. (1990). Neurotrophic and neurotoxic efects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science, 250, 279-282.
23. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, Chowbay B, Wen JY, Chan E, Cao J, Li CG, Zhou SF. (2007). Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr Drug Metab, 8, 365-378.
24. Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, Cao G, Wang Z. (2007). Protective efects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol, 564, 18-25. (Pubitemid 46946844)
25. Zhao B. (2009). Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem Res, 34, 630-638.
26. Zheng XH, Zhang QS, Wang SX, Zhao XF. (2007). Preparation of β-phenyl-α-hydroxypropionic acid derivatives for treatment of cardiovascular and cerebrovascular diseases. PCT Int Appl, 46 pp. WO 2007131446, A1 20071122, CAN 150:514768, AN 2009:647929.
27. Zhou L, Zuo Z, Chow MS. (2005). Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol, 45, 1345-1359. (Pubitemid 41643896)
28. Zhu X, Su B, Wang X, Smith MA, Perry G. (2007). Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci, 64, 2202-2210. (Pubitemid 47347959)